|Back to main|
1/4/2011 2:02:32 PM
Healthcare giant Johnson & Johnson ( JNJ ) on Tuesday saw its price target and earnings estimates lowered by analysts at Goldman Sachs.
The firm said it cut its estimates for JNJ through 2012, citing expectations of a slower recovery. Goldman maintained its "Neutral" rating on JNJ and introduced a new $59 price target, which implies a 6% downside to the stock's Monday closing price of $62.82.
Johnson & Johnson shares rose 36 cents, or +0.6%, in premarket trading Tuesday.
The Bottom Line
Johnson & Johnson ( JNJ ) is a "Recommended" dividend stock, holding a Dividend.com DARS™ Rating of 3.5 out of 5 stars.